Tasquinimod
Cat. No.：YN290063
CAS No. ：254964-60-8
| 产品名称: | Tasquinimod |
| CAS No.: | 254964-60-8 |
| Chemical Name: | 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide |
| Synonyms: | 他喹莫德; ABR-215050 |
| 分子量: | 406.36 |
| 分子式: | C₂₀H₁₇F₃N₂O₄ |
| SMILES: | O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2OC)N(C)C3=CC=C(C(F)(F)F)C=C3 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Tasquinimod是一种口服抗血管生成剂，有潜力用于去势抵抗性前列腺癌的研究。Tasquinimod与HDAC4Zn2+结合结构域结合的Kd值为10-30 nM。Tasquinimod 也是一种S100A9抑制剂。 |
| IC50和靶点: | [{name:"HDAC4:10-30 nM (Kd)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Isaacs, J.T.The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancerExpert Opin. Inv. Drugs19(10),1235-1243(2010)
Mehta, A.R., and Armstrong, A.J.Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospectsTher. Adv. Urol.8(1),9-18(2016)
